Isoniazid Tablets Manufacturer & Exporter

Product Overview
Key Features
Therapeutic Uses
Dosage Form Advantages

Genliva Wellness LLP manufactures Isoniazid Tablets for tuberculosis treatment and preventive antitubercular therapy programs. The formulation is widely incorporated into multidrug TB treatment regimens for pulmonary and extrapulmonary tuberculosis management in institutional and outpatient healthcare systems.

Isoniazid interferes with mycolic acid synthesis required for the bacterial cell wall of Mycobacterium tuberculosis, leading to suppression of tuberculosis bacterial growth. The medicine is frequently utilized in active TB treatment programs as well as preventive therapy protocols in high-risk populations.

Genliva Wellness LLP specializes in antitubercular pharmaceutical manufacturing in Gujarat supplying TB treatment formulations for government healthcare initiatives, institutional procurement agencies, pharmaceutical distributors, and international medicine export markets.

Isoniazid Tablets are formulated for antitubercular therapy and TB management.

Oral antitubercular pharmaceutical formulation
Frequently utilized in multidrug TB treatment regimens
Activity against Mycobacterium tuberculosis organisms
Optimized tablet formulation for oral administration
Manufactured using premium pharmaceutical ingredients
Intended for long-term tuberculosis treatment programs

This formulation is prescribed in tuberculosis treatment and prevention protocols.

Treatment of pulmonary tuberculosis
Management of extrapulmonary TB conditions
Administered in multidrug antitubercular therapies
Utilized in preventive TB treatment programs
Targets tuberculosis bacterial growth pathways
Frequently selected in institutional TB care systems

Isoniazid Tablets deliver targeted antitubercular therapy for TB management.

Valuable in multidrug tuberculosis treatment
Frequently preferred in preventive TB programs
Effective oral antitubercular administration
Useful in long-term tuberculosis care protocols
Important component in institutional TB therapies
Maintains strong antitubercular pharmaceutical performance